Overview

IGC Pharma, Inc. (“IGC,” the “Company,” “we,” “us,” or “our”) is a clinical-stage biotechnology company focused on the development of novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary emphasis on Alzheimer’s disease. The company’s core strategy is to address high-burden symptoms and underlying disease mechanisms through differentiated pharmaceutical formulations, supported by targeted clinical development and data-driven research approaches.

Life Sciences Segment

IGC Pharma’s lead product candidate, IGC-AD1, is currently being evaluated in the CALMA, a randomized, double-blind, placebo-controlled Phase 2 clinical trial for the treatment of agitation in Alzheimer’s dementia. The company believes IGC-AD1 has the potential to act within two weeks, which could significantly improve patient care and represents a potential breakthrough in managing Alzheimer’s-related agitation. Beyond IGC-AD1, the company’s development pipeline includes additional early-stage therapeutic candidates targeting Alzheimer’s disease mechanisms.

MINT-AD – Artificial Intelligence Platform

The company is developing a proprietary Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD), an artificial intelligence (AI) platform designed to enhance the detection and management of Alzheimer’s disease. MINT-AD is intended to transition AD diagnostics from specialized, high-cost environments to primary care settings, rural areas, and underserved populations.

The Market Opportunity and Diagnostic Gap

According to the World Alzheimer Report, an estimated 400 million individuals globally may carry AD-related pathology prior to the onset of clinical symptoms. MINT-AD is intended to bridge the “diagnostic gap” by offering a cost-effective, non-invasive alternative for early cognitive risk assessment.

Proprietary Technology and Architecture

MINT-AD leverages a “Transformer” architecture, a state-of-the-art deep learning model, to harmonize and analyze diverse, multimodal datasets, including neuroimaging, biomarkers, lifestyle and environmental data, and cognitive metrics.

Use of MINT-AD

The platform is designed to support the clinical workflow through three primary objectives: risk stratification, predictive modeling, and structured plan support.

Our Business Strategy

The company’s business strategy includes completing the CALMA trial, advancing tox studies to enable disease modifying trials with IGC-AD1, applying for non-dilutive grants, advancing TGR-63 as a potential therapeutic for AD, and strengthening clinical credibility and visibility.

The Global Economic Environment

In addition to industry-specific factors, the company is exposed to economic cycles and global economic conditions that may impact its operations, including currency fluctuations, capital and exchange controls, inflation, restrictive government actions, changes in intellectual property, and impacts of political or civil unrest or military action.

Business Updates

During the three months ended June 30, 2026, the company continued to advance the CALMA clinical trial, reached its previously disclosed target enrollment of 146 patients, and announced the beta version of its Agentic Harmonization Assistant (AHA) platform.